The research carried out in Dr. Pandolfi’s laboratory has been seminal to elucidating the molecular mechanisms and the genetics underlying the pathogenesis of leukemias and solid tumors, as well as in modeling these cancers in the mouse. Dr. Pandolfi and his team have characterized the function of the fusion oncoproteins and the genes involved in the chromosomal translocations of acute promyelocytic leukemia (APL), as well as of major tumor suppressors such as PTEN, PML and p53, and novel cancer genes such as POKEMON and INPP4B. The elucidation of the molecular basis underlying the pathogenesis of APL has led to the development of novel and effective therapeutic strategies. As a result of these efforts, APL is now considered a curable disease. Additional novel therapeutic concepts have emerged from this work and are currently being tested in clinical trials. More recently, Dr. Pandolfi and colleagues have presented a new theory describing how RNAs, both protein coding and non-coding, exert their biological functions with profound implications for human genetics, cell biology and cancer biology.
Dr. Pandolfi is also a member of the following organizations:
1997-Present; Member, American Society of Hematology
1999-Present; Member, American Association for Cancer Research
2006-Present; Member, American Society for Clinical Investigation (ASCI)
2006-Present; Member, American Association of Physicians (AAP)
2007-Present; Member, European Molecular Biology Organization (EMBO)
2013-Present; Member, American Association for the Advancement of Science